197 related articles for article (PubMed ID: 22886783)
1. C-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis.
Mann DM; Shimbo D; Cushman M; Lakoski S; Greenland P; Blumenthal RS; Michos ED; Lloyd-Jones DM; Muntner P
Clin Cardiol; 2013 Jan; 36(1):15-20. PubMed ID: 22886783
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
4. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Kones R
Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".
Ridker PM; Macfadyen JG; Nordestgaard BG; Koenig W; Kastelein JJ; Genest J; Glynn RJ
Circ Cardiovasc Qual Outcomes; 2010 Sep; 3(5):447-52. PubMed ID: 20736443
[TBL] [Abstract][Full Text] [Related]
7. Prevention of atherosclerosis in patients living with HIV.
De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
[TBL] [Abstract][Full Text] [Related]
8. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
9. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
[TBL] [Abstract][Full Text] [Related]
11. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
Peña JM; Aspberg S; MacFadyen J; Glynn RJ; Solomon DH; Ridker PM
JAMA Intern Med; 2015 Feb; 175(2):171-7. PubMed ID: 25437881
[TBL] [Abstract][Full Text] [Related]
12. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.
Glynn RJ; MacFadyen JG; Ridker PM
Clin Chem; 2009 Feb; 55(2):305-12. PubMed ID: 19095726
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
14. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
15. Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.
Blaha MJ; Rivera JJ; Budoff MJ; Blankstein R; Agatston A; O'Leary DH; Cushman M; Lakoski S; Criqui MH; Szklo M; Blumenthal RS; Nasir K
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1430-8. PubMed ID: 21474823
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED; Blumenthal RS
J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
Rubba P; Marotta G; Gentile M
Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
[TBL] [Abstract][Full Text] [Related]
18. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
[TBL] [Abstract][Full Text] [Related]
19. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Albert MA; Glynn RJ; Fonseca FA; Lorenzatti AJ; Ferdinand KC; MacFadyen JG; Ridker PM
Am Heart J; 2011 Jul; 162(1):106-14.e2. PubMed ID: 21742096
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
